(NYSE:AZN – Get Rating) and (NYSE:SNY – Get Rating) are both companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations. Profitability This table compares and ‘s net margins, return on equity and return on assets. […]
AstraZeneca PLC(NASDAQ:AZN): The pharma industry is well-placed to benefit from the rise of chronic diseases and an aging population. Moreover, given the stable demand for medicines, the industry is relatively unaffected by macroeconomic uncertainty. Therefore, it could be wise for investors to buy fundamentally strong pharma stocks AstraZeneca (AZN) and Novartis (NVS). Let’s discuss…
Brokerages expect that AstraZeneca PLC (NYSE:AZN – Get Rating) will report sales of $10.46 billion for the current quarter, according to Zacks. Two analysts have provided estimates for AstraZeneca’s earnings, with the lowest sales estimate coming in at $10.24 billion and the highest estimate coming in at $10.68 billion. AstraZeneca posted sales of $8.22 billion […]
Wall Street analysts predict that AstraZeneca PLC (NYSE:AZN – Get Rating) will post earnings per share of $0.78 for the current quarter, Zacks reports. Two analysts have made estimates for AstraZeneca’s earnings. The highest EPS estimate is $0.80 and the lowest is $0.75. AstraZeneca reported earnings per share of $0.45 in the same quarter last […]
StockNews.com began coverage on shares of Astrazeneca (NYSE:AZN – Get Rating) in a research report released on Thursday. The brokerage issued a hold rating on the stock. Shares of AZN opened at $66.81 on Thursday. Astrazeneca has a 12 month low of $48.26 and a 12 month high of $67.55. About Astrazeneca (Get Rating) AstraZeneca […]